“GammaDelta Therapeutics is taking a whole new approach to T cells by focusing on the gamma-delta variety, which may have potential in allogeneic cell therapy. Since the company raised seed funding from the likes of Abingworth in September 2016 and recruited oncology veteran Paolo Paoletti to lead the company in May last year, GammaDelta signed a major partnership with Takeda to develop its technology for cancer and autoinflammatory diseases. While it’s still at an early stage of scientific and business development, we’re looking forward to seeing where GammaDelta goes this year.”

Read the full article: Happy 2018, Here Are the Top 9 European Biotech Companies To Watch on Labiotech.eu